THE BLEEDING RISK TREATMENT PARADOX AT THE PHYSICIAN 1 AND HOSPITAL LEVEL: IMPLICATIONS FOR REDUCING BLEEDING IN PATIENTS UNDERGOING PCI.

[1]  H. Gurm,et al.  Primary and Secondary Vascular Access Site Complications Associated With Percutaneous Coronary Intervention: Insights From the BMC2 Registry. , 2019, JACC. Cardiovascular interventions.

[2]  S. Jolly,et al.  Ultrasound Guidance in Femoral Artery Catheterization: A Systematic Review and a Meta-Analysis of Randomized Controlled Trials. , 2019, The Journal of invasive cardiology.

[3]  A. Parkhomenko,et al.  Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation , 2019, The New England journal of medicine.

[4]  Brandon L. Rahn,et al.  Reversing the “Risk‐Treatment Paradox” of Bleeding in Patients Undergoing Percutaneous Coronary Intervention: Risk‐Concordant Use of Bleeding Avoidance Strategies Is Associated With Reduced Bleeding and Lower Costs , 2018, Journal of the American Heart Association.

[5]  C. Held,et al.  Bivalirudin versus Heparin Monotherapy in Myocardial Infarction , 2017, The New England journal of medicine.

[6]  J. Messenger,et al.  Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. , 2017, Journal of the American College of Cardiology.

[7]  J. Spertus,et al.  Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. , 2016, American heart journal.

[8]  G. Wilensky.  Changing Physician Behavior Is Harder Than We Thought. , 2016, JAMA.

[9]  S. Pancholy,et al.  Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. , 2016, The American journal of cardiology.

[10]  B. Heniford,et al.  Systematic Review of Randomized Controlled Trials Comparing Manual Compression to Vascular Closure Devices for Diagnostic and Therapeutic Arterial Procedures. , 2015, Surgical technology international.

[11]  Y. Miao,et al.  Network Meta-analysis of Randomized Trials on the Safety of Vascular Closure Devices for Femoral Arterial Puncture Site Haemostasis , 2015, Scientific Reports.

[12]  Mandeep Singh.  Bleeding avoidance strategies during percutaneous coronary interventions. , 2015, Journal of the American College of Cardiology.

[13]  J. Spertus,et al.  Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks , 2015, BMJ : British Medical Journal.

[14]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[15]  Mandeep Singh,et al.  An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.

[16]  S. Marso,et al.  Comparison of Bivalirudin and Radial Access Across a Spectrum of Preprocedural Risk of Bleeding in Percutaneous Coronary Intervention: Analysis From the National Cardiovascular Data Registry , 2013, Circulation. Cardiovascular interventions.

[17]  W. Weaver,et al.  Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). , 2013, JACC. Cardiovascular interventions.

[18]  M. Matheny,et al.  Risk‐Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention , 2013, Journal of the American Heart Association.

[19]  J. Spertus,et al.  Pre-procedural estimate of individualized bleeding risk impacts physicians' utilization of bivalirudin during percutaneous coronary intervention. , 2013, Journal of the American College of Cardiology.

[20]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[21]  J. Messenger,et al.  The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention , 2013, Heart.

[22]  Sunil V. Rao,et al.  Bleeding avoidance strategies. Consensus and controversy. , 2011, Journal of the American College of Cardiology.

[23]  John A Spertus,et al.  Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. , 2010, JAMA.

[24]  E. Mahoney,et al.  The impact of bivalirudin on percutaneous coronary intervention-related bleeding. , 2010 .

[25]  F. Biancari,et al.  Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty. , 2010, American heart journal.

[26]  K. Matin,et al.  An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. , 2016, American heart journal.

[27]  Juan Merlo,et al.  Appropriate assessment of neighborhood effects on individual health: integrating random and fixed effects in multilevel logistic regression. , 2005, American journal of epidemiology.